Novo Nordisk, Roche gain upgrades from HSBC

Novo Nordisk, Roche gain upgrades from HSBC

HSBC upgrades Novo Nordisk and Roche to buy, citing strong drug pipelines and growth prospects. Read more here.

Novo Nordisk A/S (NYSE:NVO) Upgraded by Hsbc Global Res to Strong-Buy Rating

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by research analysts at Hsbc Global Res from a “hold” rating to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports. A number of other analysts have also recently commented on the stock. Morgan Stanley cut shares of Novo Nordisk A/S from an “overweight” […]